Strategies for managing cytomegalovirus in transplant recipients

被引:29
|
作者
Razonable, Raymund R. [1 ]
机构
[1] Mayo Clin, Coll Med, William J von Liebig Transplant Ctr, Div Infect Dis,Dept Internal Med, Rochester, MN 55905 USA
关键词
cytomegalovirus; outcome; preemptive therapy; prophylaxis; transplantation; valganciclovir; GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS; GUIDING PREEMPTIVE THERAPY; CMV-HYPERIMMUNE GLOBULIN; HEMATOPOIETIC STEM-CELL; HIGH-RISK; CLINICAL UTILITY; ORAL GANCICLOVIR; INTRAVENOUS GANCICLOVIR; ALLOGRAFT-REJECTION; VALGANCICLOVIR PROPHYLAXIS;
D O I
10.1517/14656566.2010.492395
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Cytomegalovirus (CMV) is the most important pathogen that affects transplant recipients, by directly causing clinical disease and by indirectly reducing patient and allograft survival. Areas covered in this review: This review provides a brief overview of the direct and indirect effects of CMV disease and the traditional and newly described factors that increase the risk of disease after transplantation. Newly acquired data in the diagnostics, prevention and treatment of CMV infection are discussed, with emphasis on guidelines for management as recently endorsed by the American Society of Transplantation and the Transplantation Society. What the reader will gain: The reader will gain up-to-date insights into the contemporary management of CMV after solid organ transplantation. Practical aspects of its diagnosis, prevention and treatment are discussed. Emerging concerns of late-onset CMV disease and antiviral resistance are also highlighted to emphasize the need to optimize CMV-prevention strategies. Take home message: Prevention of CMV disease is an important goal in the management of solid organ transplant recipients. The efficacy of CMV prevention should be measured not only by the significant reduction in CMV incidence but, as importantly, by the improvement in long-term allograft and patient survival.
引用
收藏
页码:1983 / 1997
页数:15
相关论文
共 50 条
  • [21] Cytomegalovirus prophylaxis in liver transplant recipients
    Molmenti, EP
    Devera, J
    Paredes, MM
    Holochek, MJ
    Lees, L
    Eustace, JA
    Diehl, AM
    Thuluvath, PJ
    Rai, R
    Montgomery, RA
    Arrazola, L
    Updyke, G
    Cooper, M
    Falta, E
    Karp, S
    Johnson, K
    Klein, J
    Klein, AS
    GASTROENTEROLOGY, 2002, 123 (01) : 82 - 83
  • [22] Cytomegalovirus in Solid Organ Transplant Recipients
    Humar, A.
    Snydman, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : S78 - S86
  • [23] Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies
    Singh, Nina
    JOURNAL OF CLINICAL VIROLOGY, 2006, 35 (04) : 474 - 477
  • [24] Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients
    Abu-Nader, R
    Patel, R
    BIODRUGS, 2000, 13 (03) : 159 - 175
  • [25] Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice
    Fernandez-Ruiz, Mario
    Arias, Manuel
    Campistol, Josep M.
    Navarro, David
    Gomez-Huertas, Ernesto
    Gomez-Marquez, Gonzalo
    Manuel Diaz, Juan
    Hernandez, Domingo
    Bernal-Blanco, Gabriel
    Cofan, Frederic
    Jimeno, Luisa
    Franco-Esteve, Antonio
    Gonzalez, Esther
    Moreso, Francesc J.
    Gomez-Alamillo, Carlos
    Mendiluce, Alicia
    Luna-Huerta, Enrique
    Maria Aguado, Jose
    TRANSPLANT INTERNATIONAL, 2015, 28 (09) : 1042 - 1054
  • [26] Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients
    Das, A
    HEPATOLOGY, 2000, 31 (02) : 311 - 317
  • [27] Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients
    Santos, C.
    Saeed, M.
    Brennan, D.
    Olsen, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 691 - 692
  • [28] Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients
    Lilleri, Daniele
    Gerna, Giuseppe
    IMMUNOTHERAPY, 2016, 8 (09) : 1135 - 1149
  • [29] Current Management Strategies for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients
    Rima Abu-Nader
    Robin Patel
    BioDrugs, 2000, 13 : 159 - 175
  • [30] EFFICACY OF CYTOMEGALOVIRUS IMMUNOGLOBULIN IN MARROW TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS PNEUMONIA
    REED, EC
    BOWDEN, RA
    DANDLIKER, PS
    GLEAVES, CA
    MEYERS, JD
    JOURNAL OF INFECTIOUS DISEASES, 1987, 156 (04): : 641 - 645